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Background—Drug-induced liver injury (DILI) is an uncommon adverse drug reaction of
increasing importance to the medical community, pharmaceutical industry, regulatory agencies
and the general public.
Objectives—The Drug-Induced Liver Injury Network (DILIN) was established to advance
understanding and research into DILI by initiating a prospective registry of patients with bona fide
DILI for future studies of host clinical, genetic, environmental and immunological risk factors.
The DILIN was also charged with developing standardized nomenclature, terminology and
causality assessment instruments.
Methods—Five clinical sites, a data coordinating centre and senior scientists from the National
Institute of Diabetes and Digestive and Kidney Diseases initiated the DILIN prospective study in
September 2004. Eligible patients are required to meet minimal laboratory or histological criteria
within 6 months of DILI onset and have other competing causes of liver injury excluded. Patients
in the general community setting with pre-existing HIV, hepatitis B virus or hepatitis C virus
infections and/or abnormal baseline liver biochemistries are eligible for enrolment. In addition,
subjects with liver injury due to herbal products are eligible to participate. Control patients without
DILI are also to be recruited in the future.
Results—All referred subjects undergo an extensive review of available laboratory, pathology
and imaging studies. Subjects who meet pre-defined eligibility criteria at the 6-month study visit
are followed for 2 years to better define the natural history of chronic DILI. Causality assessment
is determined by a panel of three hepatologists who independently assign a causality score ranging
from 1 (definite) to 5 (unlikely) as well as a severity score ranging from 1 (mild) to 5 (fatal).
During the first 3 years, 367 subjects were enrolled into the DILIN prospective study.
Conclusion—DILIN is a multicentre research network charged with improving our
understanding of the aetiologies, risk factors and outcomes of DILI in the US. The network is
meeting the targeted enrolment of ten patients per month and is developing a repository of clinical
data and biological samples for future studies of DILI pathogenesis and outcome.
Background
Drug-induced liver injury (DILI) is the leading cause of acute liver failure in the US and the
most common reason for US FDA regulatory actions regarding approved medications.[1,2]
Implicated drugs include not only prescription medications but also herbal products and
over-the-counter dietary supplements and medications.[3,4] Persons who develop
hepatocellular DILI with jaundice have at least a 10% chance of dying from the injury and
DILI patients that progress to acute liver failure have only a 25% chance of spontaneous
recovery.[1,5] While DILI caused by a particular agent can be serious, it is relatively
uncommon, with an estimated frequency that ranges from 1 per 10 000 to 1 per 10 000 000
patient-years of exposure. Therefore, the low incidence of DILI coupled with the limited
knowledge of the biochemical mechanism(s) or pathways responsible for this ‘idiosyncratic’
adverse event make it difficult to identify high-risk patients.[6] Some investigators have
postulated the importance of reactive metabolites or aberrant host metabolism and immune
responses in the pathogenesis of DILI but the precise molecular mechanism(s) involved are
largely unknown.[6,7] Furthermore, pre-clinical testing does not provide a reliable
assessment of the hepatotoxic risk of new medications, and because DILI is a rare event,
pre-marketing clinical studies conducted in highly selected populations over a relatively
short period of time also may not detect a potential for liver injury. Therefore, the
hepatotoxicity of a specific medication often becomes apparent only after regulatory
approval and when the drug is used by large numbers of unselected patients in the general
population.[2,6] Even then, voluntary post-marketing surveillance systems such as the FDA
MedWatch programme frequently lag behind in detecting ‘hepatotoxic signals’ from newly
approved drugs.[8] Finally, the biochemical, clinical and histological features of DILI from
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initial onset to clinical presentation can not only mimic most other known forms of acute
and chronic liver disease but can also vary substantially with a single agent.[9,10] Thus, at
present, there is no objective ‘gold standard’ for diagnosing DILI and its identification
largely relies on excluding other more common causes of liver disease and having a
‘compatible’ time of onset and evolution.[2,10]
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) established
the Drug-Induced Liver Injury Network (DILIN) in 2003 to advance understanding and
research into DILI by selecting five clinical sites and a data coordinating centre (DCC) that
had submitted competitive grant applications.[11,12] In this article we present the rationale,
design and methods of the prospective DILIN study.
Aims and Objective
The primary aim of the prospective DILIN study is to identify a large number of patients
with bona fide DILI that will allow for collection of epidemiological data and biological
samples for future mechanistic studies. The DILIN study aims to do this by creating within 6
months of onset a registry and tissue bank from people who have experienced liver injury
due to prescription and over-the-counter drugs as well as herbal products. A prospective
registry will allow investigation into clinical, immunological, environmental and genetic risk
factors by comparing DILI cases with matched control patients with a similar drug exposure
history but without evidence of liver injury. Since the natural history of DILI is not well
understood, all of the DILI cases are to be re-evaluated 6 months after enrolment. All
participants agree to be re-contacted for up to 20 years for potential participation in
additional studies, such as those that explore the relationship between genotype and
phenotype or pedigree studies. Lastly, the DILIN is charged with developing and testing




Eligible patients with suspected DILI are referred to one of the five DILIN sites or their
satellite affiliates. Patients may be referred by a physician/medical provider at one of the
clinical sites, a physician/medical provider at a nearby location or hospital or may refer
themselves. The DILI event must be attributable to one or more prescription or over-the-
counter medications or herbal products. Subjects are categorized as having ‘standard DILI’
if they did not have known liver disease prior to starting the suspect medication. In contrast,
subjects with known liver disease prior to DILI onset, such as chronic hepatitis B virus
(HBV) or chronic hepatitis C virus (HCV) infection or fatty liver disease, are referred to as
‘liver DILI’ patients.
Baseline Study Visit
After an informed consent document is signed, all relevant laboratory, pathology and
imaging studies are reviewed to ensure that referred patients meet entry criteria. A complete
history and physical examination are undertaken and detailed information regarding
medications, past medical history, drug intolerances and symptoms at DILI onset is obtained
(table I). In particular, the patient is questioned about the lifetime use of the suspect
medication and agents in the same therapeutic class identified from an electronic database
(Lexi-Comp®, Lexi-Comp Inc., Hudson, OH, USA). In addition, recent alcohol
consumption, medication compliance and smoking history are obtained using interviewer-
administered questionnaires. Adult participants also complete the Short Form-36 quality-of-
life form (Rand Corporation, Arlington, VA, USA) and children complete the Pediatric
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quality-of-life form (MAPI Research Institute, Lyon, France).[13,14] These instruments were
selected because of their established validity, brevity and frequent use in other studies of
patients with liver disease.
The type of liver injury at DILI onset is classified as hepatocellular, cholestatic or mixed by
the R ratio, which compares ALT and alkaline phosphatase levels in multiples of their upper
limit of normal (ULN) based upon the first available values after DILI onset. The R ratio is
calculated by the formula R = (ALT/ULN)/(alkaline phosphatase/ULN). For eligible patients
with acute hepatocellular injury (i.e. R > 5), diagnostic tests required at enrolment include:
total and, if positive, IgM antibody to hepatitis A virus, hepatitis B surface antigen (HBsAg),
antibody to hepatitis B core antigen, anti-HCV and if positive HCV RNA, anti-nuclear
antibody, anti-smooth muscle antibody, IgM antibody to cytomegalovirus, Epstein Barr-
virus (EBV) serologies or a monospot test and ceruloplasmin if the patient is aged <50
years. A cross-sectional abdominal imaging study such as an ultrasound, abdominal CT or
MRI is also required. Subjects with a mixed (i.e. 5 > R > 2) or cholestatic (R < 2)
biochemical profile at DILI onset are also required to have all of the above completed as
well as an anti-mitochondrial antibody test. Serum α1-antitrypsin and iron indices are
recorded, if available, but are not mandatory. Available liver biochemistry results starting 8
weeks prior to initiation of the suspect drug through the baseline study visit are recorded as
well as the results of other selected laboratory tests (e.g. haemoglobin, white blood cell
count and serum creatinine).
Urine and whole blood samples are collected at the baseline study visit. Plasma, serum and
lymphocytes for DNA extraction, EBV immortalization and proliferation assays are
obtained and stored at the NIDDK biosample repository (Rutgers University, Piscataway,
NJ, USA). Routine laboratory tests obtained at each study visit include a urinalysis,
complete blood count, liver biochemistries, international normalized ratio (INR), serum
amylase, lipase, creatinine phosphokinase, γ-glutamyl transpeptidase and lactate
dehydrogenase levels. For HIV-infected patients and those with known chronic HBV or
HCV, detailed data regarding prior disease status including available CD4 counts and viral
test results as well as antiviral treatment are collected. The site investigator also generates a
written clinical narrative summarizing the DILI event for causality assessment. For patients
with DILI due to herbal products, the brand name, manufacturer and ingredients of each
product are recorded. In addition, samples of the suspect herbal product are collected and
forwarded to the US National Institutes of Health (NIH) for future analysis of ingredient
content.
Inclusion and Exclusion Criteria—Participants are required to have experienced a DILI
event within 6 months of the baseline visit (table II). The DILI onset date is defined as the
first date after starting the suspect medication wherein the subject met the laboratory entry
criteria. Both children and adults are eligible to participate, the minimum subject age being 2
years. Inclusion laboratory criteria are a serum AST or ALT >5 times ULN (or pretreatment
baseline if baseline levels are elevated) on two separate occasions. Alternatively, subjects
with serum alkaline phosphatase levels >2 times ULN (or baseline if the baseline level is
abnormal) on two consecutive occasions may qualify. In addition, subjects who develop a
serum total bilirubin of greater than 2.5 mg/dL or an INR above 1.5 in the absence of a
competing cause of hyperbilirubinaemia or hypoprothrombinaemia, respectively, are
eligible.
Exclusion criteria are known or suspected paracetamol (acetaminophen) overdose as well as
a history of bone marrow or liver transplant prior to DILI onset. Subjects with pre-existing
immune-mediated liver disease such as autoimmune hepatitis are also excluded. However,
subjects with unexplained abnormal liver biochemistries or with pre-existing chronic HBV,
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chronic HCV and HIV infection are allowed to participate in light of the high prevalence of
these conditions in the general population.[15-17]
Six-Month Study Visit
At the 6-month study visit, interval medical history, laboratory tests, medication use and
liver imaging are reviewed (table I). In subjects with pre-existing chronic HBV, a
quantitative HBV DNA, hepatitis B e antigen and antibody measurements are obtained.
Similarly, in subjects with pre-existing chronic HCV, a quantitative HCV RNA
measurement is obtained and an HIV RNA and CD4 count are obtained in patients with HIV
infection. Subjects with evidence of ‘chronic DILI’ undergo a cross-sectional imaging study
while those without evidence of persistent liver injury are asked to provide contact
information for future studies.[18] A written narrative summarizing any data that may
influence causality assessment such as re-challenge, new medical diagnoses or liver biopsy
findings is generated.
Chronic Drug-Induced Liver Injury
Chronic DILI is defined at 6 months after DILI onset as one of the following: (i) for subjects
with normal or unknown baseline liver biochemistries, a serum AST, ALT, alkaline
phosphatase, INR or total bilirubin that is persistently elevated on two separate occasions;
(ii) for liver DILI subjects, a serum AST, ALT, alkaline phosphatase, INR or total bilirubin
level that exceeds 1.25 times the baseline value on two separate occasions; (iii) any evidence
of portal hypertension such as ascites on imaging, varices on upper endoscopy or clinical
evidence of hepatic encephalopathy; (iv) any histological evidence of persistent liver injury
at least 6 months after DILI onset; or (v) any radiological evidence of chronic liver disease
such as ascites, hepatomegaly, nodular liver or intra-abdominal varices. Subjects with pre-
existing chronic HBV or HCV infection, liver transplant recipients since the baseline visit
and patients with cirrhosis or clinical evidence of portal hypertension before starting the
suspect medication are excluded from the chronic DILI protocol.
Subjects with chronic DILI are seen at 12 and 24 months after the baseline visit wherein
incremental medical history, medication use, laboratory and imaging studies and
questionnaires are completed. A final written narrative is also generated by the site
investigator summarizing the course of the DILI episode. For subjects who die during
follow-up, a death narrative recording whether the death was attributable to a liver or non-
liver related cause is generated by the site investigator for review by the causality
committee.
Liver Histopathology Review
Liver biopsy is not part of the protocol. When performed as part of routine care, the written
pathology report is incorporated into the case report and considered during causality
assessment. When available, six unstained slides are also sent to the DILIN pathologist, Dr
David Kleiner, for formal scoring and assessment of histopathological features of DILI.[19]
The centralized histological assessment is not included in the causality review process but is
retained in the database along with representative photomicrographs.
Causality Assessment
Because DILI is a clinical diagnosis of exclusion, a formal and standardized approach to
causality assessment was established in the DILIN.[5,20,21] Causality is assessed with the
widely used Roussel Uclaf Causality Assessment Method (RUCAM) as well as by ‘expert
consensus’.[22] The RUCAM provides a semi-quantitative assessment of causality by
assigning −3 to +3 points to each of six domains. A final summary score allows
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categorization of causality as highly probable (>8), probable (6–8), possible (3–5), unlikely
(1–2) or excluded (<0). For expert consensus, a DILIN causality committee was established
that consists of seven voting members including the five clinical site investigators (or their
designees) and a representative from the DCC and the NIDDK. Three causality committee
members (the clinical site principal investigator and two others) receive key clinical,
laboratory and diagnostic data abstracted from the DILIN baseline visit and clinical
narrative (table I). The three committee members each independently calculate a RUCAM
score using forms developed for this purpose and also assign a DILIN causality score
ranging from 1 (definite) to 5 (unlikely). To standardize terminology and attempt to make
causality assessment by expert opinion more objective, definitions were developed for each
causality level (table III). These definitions included three elements: (i) a percentage
likelihood that the drug caused the liver injury (>95%, 75–95%, 50–74%, 25–49% and
<25%); (ii) standard legal terms to help define the weight of the evidence for causality (i.e.
‘beyond a reasonable doubt’, ‘clear and convincing evidence’ and ‘the preponderance of
evidence’); and (iii) a set of criteria describing the clinical features that match the known
timing and pattern of injury. These definitions were developed during the initial years of the
DILIN study in an attempt to provide guidance for the expert opinions.
In cases involving more than one implicated drug, an overall causality score for the DILI
event is assigned as well as scores for up to three different medications. When the DILIN
causality scores of the three assigned reviewers do not agree, the case is discussed by the
entire committee on a teleconference wherein a final consensus score is assigned. Finally,
the severity of the DILI episode is categorized on a scale of 1–5 as summarized in table IV.
Controls
Once a minimum of 15 standard DILI cases due to a single medication are enrolled, up to
three age-matched control subjects per case will be identified to test for differences in
clinical risk factors. A minimum of 15 cases are required to have adequate power (i.e. 80%)
to detect a difference in a risk factor with a prevalence of 20% in the control subjects that is
strongly associated with DILI and has an odds ratio of 12 or greater. Controls for clinical
and environmental risk factors may consist of individuals who were exposed to the suspect
medication for the same or longer period of time than the index case but did not develop
liver injury. However, it may not be possible to identify controls for cases with more than
one suspect medication, which has been noted in 20% of the patients enrolled to date.[23]
Therefore, recruitment of controls is being deferred until an adequate number of bona fide
cases due to a specific medication are enrolled. Furthermore, it is possible that population
controls matched by age and ethnicity may be selected for DILI cases if genetic association
studies for rare phenotypes such as DILI can be accurately done using population
controls.[24] By pooling the DILI cases together for genomic studies, there will be a greater
likelihood of detecting significant associations between genetic polymorphisms and DILI
susceptibility. For example, if 1000 DILI cases and 3000 controls were analysed, we would
have adequate power (i.e. 80%) to detect a polymorphism that occurs in 1% of the controls
with an odds ratio of 2.75 or greater or a polymorphism that occurs in 0.1% of the controls
with an odds ratio of 8.0 or greater. A DILIN genomics committee will be developed to help
select the optimal genomics platform to use and develop a strategy to recruit and enrol
control subjects.
Data Coordinating Centre
In addition to arranging study meetings and conference calls, the DCC is responsible for the
development of case report forms and maintenance of a computerized study database.
Double data entry is used at the DCC and data queries are generated to clarify potential
errors or missing values on the case report forms along with annual site audits to verify
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source documents and protocol adherence. Enrolment and specimen tracking reports are
prepared by the DCC as well as data analyses for various abstracts and presentations. The
DCC also submits de-identified information on adjudicated cases to the FDA by completing
a MEDWATCH form that includes data regarding the suspect drug, concomitant
medications, medical history, diagnostic evaluation and clinical outcome. A certificate of
confidentiality from the National Institute of Mental Health (NIMH) was obtained for the
study to assure the confidentiality of the acquired research data.
Results
Recruitment and Retention Procedures
The projected enrolment rate of two DILI patients per centre per month has been achieved
(figure 1). Most centres sent recruitment brochures to local physicians and gastroenterology
specialists in their regions. In addition, the site investigators have given educational
seminars on DILI at various venues including medical grand rounds, divisional conferences
and regional and national continuing medical education and professional society meetings.
The DILIN steering committee has also developed a central website (http://
dilin.dcri.duke.edu) and co-sponsored several research meetings on DILI including the
American Association of the Study of Liver Disease’s Single Topic Clinical Research
conference on DILI. An international workshop on standardization of nomenclature and
causality assessment of DILI is also being planned for December 2008 (see http://
www3.niddk.nih.gov/fund/other/conferences.shtml).
All clinical sites have attempted to develop collaborations with other investigators in their
region. For example, the University of Connecticut (principal investigator [PI]: Dr Herbert
Bonkovsky) established ties with four other regional academic medical centres wherein
patients can be recruited and enrolled into the study at those approved satellite sites. As of
October 2007, these four satellite sites have contributed 16 of the 64 (25%) patients enrolled
through the University of Connecticut. At the University of North Carolina (PI: Dr Paul
Watkins), the DILIN study staff travel to other academic institutions in the state (Duke
University Medical Center in Durham, Carolinas Medical Center in Charlotte) or elsewhere
(Georgetown University Hospital in Washington, DC, USA) to recruit and enrol patients.
This effort has provided 12 of the 85 (14%) patients enrolled through this site. A third
recruitment strategy at the University of Michigan (PI: Dr Robert J. Fontana) has been to
develop a multi-institutional statewide DILIN with regularly scheduled face-to-face
meetings, electronic newsletters and educational exercises for participants. In this model, all
of the subjects are seen at the primary clinical site although investigators at other nearby
institutions are intimately involved in screening and enrolling subjects. Recruitment at the
University of California, San Francisco, CA, USA (PI: Dr Timothy Davern) and Indiana
University, Indianapolis, Indiana, USA (PI: Dr Naga Chalasani) has relied upon referrals to
their medical centres but all patients are seen at the central site under the auspices of a
general clinical research centre.
The most common reason for non-participation in the study has been subject refusal in 30%
of individuals (e.g. due to travel distance or illness), followed by failure to meet laboratory
entry criteria or a competing cause of liver injury identified in 19% (table V). Some referred
patients with suspected DILI did not qualify for the study based upon the laboratory entry
criteria or the strict requirement for referral within 6 months of DILI onset. As a result, an
exemptions committee was formed consisting of an NIH representative, a member of the
DCC and a rotating site investigator. To request an exemption, a site investigator submits a
brief narrative and rationale to allow the patient into the study. From June 2005 to October
2007, there were 40 protocol exemptions submitted, of which 34 were approved and
enrolled in the study and six were denied (table VI).
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DILI is an infrequent but increasingly recognized adverse event that affects the current and
future practice of medicine. DILI is the single most common reason for the FDA to remove
or restrict medications in the marketplace.[25-27] In addition, DILI is a frequent reason for
drugs in development not to receive FDA approval and a leading reason to stop investigating
drug candidates in early clinical development.[28,29] Unfortunately, preclinical testing in
animal models and in vitro toxicology systems have provided minimal assistance in
identifying potentially hepatotoxic drugs.[2] Clearly, an improved understanding of the risk
factors and mechanisms of idiosyncratic DILI in humans is needed to allow otherwise safe
and effective medications to remain available to the general population.
Challenges to performing clinical studies of DILI include the need to exclude more common
causes of liver injury and the lack of standardized diagnostic criteria. Furthermore, the
generally low frequency of DILI with most available drugs has made it difficult to recruit
patients even in referral centres.[30,31] In Northern France, a prospective study identified 95
suspected DILI subjects from a population of 81 000 inhabitants over a 3-year period.[32]
However, after alternative causes of liver injury were excluded, only 34 patients (36%) with
presumed DILI were enrolled giving an estimated annual incidence of DILI of 14 per 100
000 patient years. Importantly, 82% of the DILI patients were never hospitalized and <30%
were referred to a gastroenterologist. Similarly, in studies from England and Spain, most
suspected DILI cases were reported by general physicians and a large proportion were
ultimately judged to be unlikely providing an estimated DILI incidence of only 1–3 per 100
000 patient years of exposure.[33,34] These observations suggest that prospective studies of
DILI need to involve a large number of practicing physicians in the community to identify
the full spectrum of DILI in the general population via a multicentre, surveillance
network.[2,11]
The DILIN prospective protocol was initiated with the intent to enrol consecutive patients
with suspected DILI at the five clinical sites in the US.[12] Cases of paracetamol
hepatotoxicity were excluded in light of multiple prior studies on the mechanism and natural
history of this common cause of acute hepatocellular injury.[35] In addition, subjects with
pre-existing immune-mediated chronic liver disease such as autoimmune hepatitis were
excluded in light of the difficulty of distinguishing a DILI episode from a disease flare.[36]
However, HIV-positive patients were targeted for enrolment into the DILIN prospective
study in light of the increasing recognition of liver-related morbidity and mortality in
subjects receiving highly active antiretroviral therapy (HAART).[15,16] Furthermore, since
up to 30% of HIV-positive patients have concomitant viral hepatitis, subjects with pre-
existing chronic HBV or HCV were also targeted for enrolment into the DILIN prospective
protocol. The generalizability of the findings from DILIN will require comparison with
other population-based studies of DILI in the US and abroad that may employ similar or
alternative recruitment methods.
The five DILIN clinical sites have enrolled ~2 cases per month at each centre with 367 total
cases enrolled into the DILIN prospective study through October 2007 (figure 1). However,
screen failures have been encountered at each site due to a multitude of reasons (table IV).
Although clinical data are not collected on screen failures, it is possible that these patients
intrinsically differ from the patients who enrol. To recruit the largest number of DILI cases,
most of the DILIN sites have developed local or regional referral networks. The two models
of satellite site development with either an off-site research team (University of
Connecticut) or use of the main site study staff at distant locations (University of North
Carolina) have had varied results. Over the next 5 years, it is expected that the number of
DILIN clinical sites will be increased to eight (see http://grants.nih.gov/grants/guide/rfa-
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files/RFA-DK-07-012). If the current rate of enrolment was to continue following expansion
of the network, it is anticipated that over 1000 DILI cases would be enrolled in the next 5
years.
Criteria for a diagnosis of DILI include identification of a suspect medication with a
plausible temporal association to the liver injury episode, exclusion of competing causes of
liver injury and comparison of the case phenotype with published reports of liver injury due
to the suspect medication. In addition, improvement of the liver injury with drug cessation is
typically observed. Finally, intentional or inadvertent re-challenge can be helpful but is
infrequently undertaken and does not always lead to reproducible liver injury.[10] In the
DILIN prospective study, extensive diagnostic serologies, laboratory tests and liver imaging
are required to exclude other more common causes of liver injury (table I). In addition, a
detailed narrative is generated to provide clinical information on other contributing factors
such as systemic illnesses and concomitant medications. Finally, the 6-month follow-up visit
allows other disease processes to be diagnosed such as occult pancreaticobiliary cancer.
Subject retention thus far has been excellent with over 82% of eligible subjects completing
the 6-month study visit.
A final goal for DILIN is to develop standardized terminology, definitions and causality
assessment instruments to be used by other research groups as well as practicing
clinicians.[12] In the DILIN prospective study, subjects are classified as ‘standard DILI’ or
‘liver DILI’ cases. The reason to include the latter group is because of the high prevalence of
fatty liver disease, abnormal liver biochemistries and viral hepatitis in the general US
population. Furthermore, inclusion of these patients may help determine if pre-existing liver
disease increases susceptibility or influences outcomes with DILI.[37,38] It is anticipated that
the level of diagnostic certainty for a DILI episode may be lower in subjects with pre-
existing liver disease due to the difficulty in distinguishing a disease flare from the effect of
a suspect medication. However, only prospective determination of causality assessment will
allow us to determine if the diagnostic criteria for ‘standard DILI’ and ‘liver DILI’ cases
should be different. Finally, multivariate modelling is planned to help identify the key
components from the extensive data collected in enrolled subjects. Development of an
evidence-based causality assessment instrument will enable the more confident diagnosis of
DILI.
An international consensus group proposed the persistence of laboratory abnormalities for
more than 3 months in subjects with acute hepatocellular DILI and 6 months in subjects with
cholestatic DILI as criteria for ‘chronic DILI’.[39,40] However, in other liver diseases such as
acute HBV or HCV infection persistence of detectable HBsAg or HCV RNA for at least 6
months is used to identify subjects with chronic infection.[41,42] Therefore, a 6-month
persistence of biochemical abnormalities in a subject with previously normal
aminotransferase levels was felt to be a reasonable criterion for ‘chronic DILI’. In addition,
clinical, histopathological or radiological abnormalities that persist 6 months after DILI
onset are proposed as diagnostic criteria for ‘chronic DILI’.[18,43,44]
Although the RUCAM is the most frequently used causality assessment instrument,
limitations include difficulty in interpreting definitions, a lack of accounting for HCV
infection and a low level of inter-observer reproducibility.[45,46] The causality categories in
the DILIN prospective study are largely clinical in nature and are designed to convey
varying levels of confidence in the diagnosis of DILI. This methodology relies on the expert
opinion of three experienced hepatologists who are provided with extensive clinical,
laboratory and imaging data from the baseline visit. In order to decrease the subjective
nature of causality assessment, a set of definitions was developed for each category using
three approaches: percentage likelihood, legal phrases and a set of conditions to support
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each level of causality (table III). Although these terms are widely used in assessing
causality in various adverse drug events, their meanings have not been standardized. The
terms of ‘definite’, ‘highly likely’ and ‘probable’ were used to define cases that were
convincingly related to the medication, whereas ‘possible’ and ‘unlikely’ were used to
define cases that were not convincingly related. Whether this approach will be generalisable
to all patients presenting with DILI remains unclear and these terms and definitions will be
prospectively evaluated and compared with more conventional approaches such as the
RUCAM.
Causality assessment is also hampered by the lack of accurate and reliable biomarkers of
DILI. Although lymphocyte stimulation or transformation assays have been proposed, they
are currently not well standardized, validated nor widely available. Thus, their role in
diagnosis amongst individual patients remains uncertain.[47] The prospective collection of
biological samples in DILIN at baseline and 6 months will hopefully provide the materials
to develop improved biomarkers. These samples will also provide invaluable resources for
the investigation of genomic, proteomic and metabolomic approaches to establishing
causality and identifying underlying mechanisms of liver DILI. Finally, DILIN is interested
in developing a web-based causality assessment instrument and comprehensive database on
DILI in collaboration with the National Library of Medicine to assist investigators interested
in DILI as well as practicing clinicians.
Conclusions
The DILIN prospective study is designed to improve our understanding of the mechanisms,
risk factors and natural history of DILI amongst children and adults in the US. Criteria for
patient enrolment, standardized terminology and causality assessment methods have been
developed as part of the DILIN prospective study. The five clinical sites have enrolled 367
subjects thus far, using a variety of recruitment methods. The study entry criteria have been
adapted and modified via the development of an exemptions committee. Causality
assessment is continuously being refined with the ultimate goal of developing a user-
friendly, reproducible and accurate causality assessment instrument. Finally, the collection
of biological samples from cases and controls will allow for genetic association studies as
well as identification of clinical, immunological and environmental risk factors for DILI
susceptibility and outcome.
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Cumulative enrolment into the Drug-Induced Liver Injury Network (DILIN) prospective
study. The observed enrolment of 367 patients has paralleled the projected rate of enrolment
of two cases per centre each month or ten cases total for the five clinical sites every month
from September 2004 to October 2007.
Fontana et al. Page 13

























Fontana et al. Page 14
Table I
Visit schedule in the Drug-Induced Liver Injury Network (DILIN) prospective study
Item Data source Baseline visit 6-mo study visit 12- and 24-mo
study visit






Pharmacy use Interview ✓
Medication compliance Interview ✓
Family history Interview ✓
Diagnostic laboratory testsd Records/visit ✓
Suspect medication use Interview/records ✓
HCV/HBV laboratory testse Records/visit ✓ ✓
Concomitant medication and
CAM use history
Interview/records ✓ ✓ ✓
Alcohol and smoking Interview ✓ ✓ ✓
Physical examination Visit ✓ ✓ ✓
Symptom score Interview ✓ ✓ ✓
Quality-of-life survey Interview ✓ ✓ ✓
Medical history Interview/records ✓ ✓ ✓
Standard laboratory tests Records/visit ✓ ✓ ✓
Research blood sample Visit ✓ ✓ ✓
Research urine sample Visit ✓ ✓ ✓
Liver imaginga Records ✓ ✓ ✓
a
Standard DILI case = normal liver biochemistries or no known liver disease before starting the suspect medication.
b
Liver DILI case = known chronic liver disease such as chronic HCV or HBV or fatty liver before starting the suspect medication.
c
Chronic DILI case = evidence of persistent laboratory, radiological or pathological abnormalities 6mo after DILI onset.
d
Not done in control patients.
e
Only in HCV/HBV liver DILI patients.
CAM=complementary and alternative medicine; DILI=drug-induced liver injury; HBV=hepatitis B virus; HCV=hepatitis C virus.
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Table II
Entry criteria for the Drug-Induced Liver Injury Network (DILIN) prospective study
Inclusion criteria
Age >2ya
Enrolled within 6 mo of liver injury onset due to a drug or herbal product
Any one of the following laboratory criteria must be present
i. If serum liver biochemistries were normal prior to starting suspect drug serum ALT >5×ULN on two consecutive occasions or
serum AST >5×ULN on two consecutive occasions or serum alkaline phosphatase >2×ULN on two consecutive occasions
ii. If serum liver biochemistries were elevated prior to starting suspect drug serum ALT >5×pre-drug average on two consecutive
occasions or serum AST >5×pre-drug average on two consecutive occasions or serum alkaline phosphatase >2×pre-drug average on
two consecutive occasions
iii. Serum total bilirubin >2.5mg/dL and an elevated AST, ALT or alkaline phosphatase (without known haemolysis or Gilbert’s
syndrome)
iv. INR >1.5 along with an elevated AST, ALT or alkaline phosphatase (without known coumadin therapy or vitamin K deficiency)
Exclusion criteria
Paracetamol (acetaminophen) hepatotoxicity
Pre-existing liver disease such as primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis or other chronic biliary tract
disease that may confound diagnosis
Liver or bone marrow transplant prior to enrolment
Identifiable competing cause of liver injury felt to be responsible for observed liver injury
a
Age restriction due to need for blood withdrawal.
DILI=drug-induced liver injury; HBV=hepatitis B virus; HCV=hepatitis C virus; INR=international normalized ratio; ULN=upper limit of
normal.
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Table III






1 = definite >95 Liver injury is typical for the drug or herbal product (‘signature’ or pattern of injury, timing of onset,
recovery).
The evidence for causality is ‘beyond a reasonable doubt’
2 = highly likely 75–95 The evidence for causality is ‘clear and convincing’ but not definite
3 = probable 50–74 The causality is supported by ‘the preponderance of evidence’ as implicating the drug but the evidence
cannot
be considered definite or highly likely
4 = possible 25–49 The causality is not supported by ‘the preponderance of evidence’; however, one cannot definitively exclude
the possibility





Key elements of the drug exposure history, initial presentation, alternative diagnoses and/or diagnostic
evaluation prevent one from determining a causality score













Fontana et al. Page 17
Table IV
Drug-induced liver injury (DILI) severity index definitionsa
Score Grade Definition
1 Mild Patient has elevation in ALT and/or alkaline phosphatase levels but total serum bilirubin is <2.5mg/dL and
INR is <1.5
2 Moderate Patient has elevation in ALT and/or alkaline phosphatase levels and serum bilirubin is ≥2.5mg/dL or INR is ≥1.5
3 Moderate–
severe
Patient has elevation in ALT, alkaline phosphatase, bilirubin and/or INR levels and patient is hospitalized or an ongoing
hospitalization is prolonged because of DILI
4 Severe Patient has elevation in ALT and/or alkaline phosphatase levels and total serum bilirubin is 2.5mg/dL or greater and
there is at least one of the following: (i) hepatic failure (INR ≥1.5, ascites or encephalopathy); (ii) other organ failure
believed to be due to DILI event
5 Fatal Patient dies or undergoes liver transplantation because of DILI event
a
In addition, cases are rated for presence or absence of symptoms (A = asymptomatic; S = symptomatic). Symptoms include fatigue, nausea,
vomiting, right upper quadrant pain, itching, skin rash, jaundice, weakness, anorexia or weight loss, which in the opinion of the investigator are due
to DILI.
INR = international normalized ratio.













Fontana et al. Page 18
Table V
Reasons for patient exclusion from the Drug-Induced Liver Injury Network (DILIN) prospective study from
September 2004 to October 2007
Site UConn Indiana UCSF UMich UNC Total
Enrolled into the study 64 83 46 89 85 367
Excluded patients (%)
 refused to participate 24 (35) 5 (25) 16 (44) 22 (39) 6 (9) 73 (30)
 did not meet laboratory entry criteria on
 two consecutive occasions
7 (10) 6 (32) 2 (6) 11 (20) 21 (32) 47 (19)
 competing cause identified 15 (22) 4 (21) 3 (8) 13 (23) 11 (17) 46 (19)
 DILI onset >6 mo from enrolment 10 (15) 0 (0) 5 (14) 0 (0) 17 (26) 32 (13)
 travel distance too far 6 (9) 2 (11) 8 (22) 4 (7) 1 (2) 21 (8)
 paracetamol (acetaminophen) hepatoxicity 0 (0) 0 (0) 1 (3) 1 (2) 8 (12) 10 (4)
 died prior to enrolment 5 (7) 2 (11) 0 (0) 3 (5) 0 (0) 10 (5)
 immune-mediated chronic liver disease 0 (0) 0 (0) 0 (0) 2 (3) 0 (0) 2 (1)
 liver or bone marrow transplant prior to DILI onset 0 (0) 0 (0) 1 (3) 0 (0) 1 (2) 2 (1)
 age <2 y 0 (0) 0 (0) 0 (0) 0 (0) 1 (2) 1 (0.5)
 other (regulatory) 1 (1) 0 (0) 0 (0) 0 (0) 0 1 (0.5)
Total 68 19 36 56 66 245
DILI = drug-induced liver injury; Indiana = Indiana University; UConn = University of Connecticut; UCSF= University of California San
Francisco; UMich = University of Michigan; UNC= University of North Carolina.
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Table VI





Age <2 y 2 2 (100)
DILI onset >6mo prior 20 17 (85)
Failed to meet biochemical
criteria
18 15 (83)
Total 40 34 (85)
DILI = drug-induced liver injury.
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